{
    "4 24 2025": {
        "importantArticles": [
            {
                "headline": "Having significant capital in the bank when investing in equities is helpful, but is by no means necessary.  If you're patient and hold on to it through the kind of market volatility we're experiencing, while occasionally purchasing more shares, that should result in excellent returns.  Let's consider two great options: Pfizer (NYSE: PFE) and Adyen (OTC: ADYE.Y).",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.933",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "2 No-Brainer Stocks to Buy With Less Than $30",
                "url": "https://finance.yahoo.com/news/2-no-brainer-stocks-buy-104500799.html"
            },
            {
                "headline": "Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the...",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3818",
                "source": "Simply Wall St.",
                "ticker": "PFE",
                "title": "With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns",
                "url": "https://finance.yahoo.com/news/67-institutional-ownership-pfizer-inc-130012784.html"
            },
            {
                "headline": "SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1027",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth",
                "url": "https://finance.yahoo.com/news/sanofi-q1-earnings-top-estimates-115900224.html"
            },
            {
                "headline": "NEW YORK, April 23, 2025--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO\u00ae) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across Pfizer\u2019s key tumor areas, including breast, genitourinary,",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7906",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting",
                "url": "https://finance.yahoo.com/news/pfizer-advances-bold-vision-future-194600237.html"
            },
            {
                "headline": "Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. HARMONi-6 is a study conducted in China sponsored",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Benzinga",
                "ticker": "PFE",
                "title": "Why Is Summit Therapeutics Stock Soaring On Wednesday?",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-stock-soaring-194743694.html"
            },
            {
                "headline": "Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1419",
                "source": "Yahoo Finance",
                "ticker": "PFE",
                "title": "Why vaccine makers aren't worried about Trump administration cuts",
                "url": "https://finance.yahoo.com/news/why-vaccine-makers-arent-worried-about-trump-administration-cuts-185027024.html"
            }
        ],
        "avgScore": -0.004633333333333317,
        "pctChange": 0.002495561369752226
    },
    "4 23 2025": {
        "importantArticles": [
            {
                "headline": "The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030.  As a result, many top healthcare companies are vying for a piece of the market, as doing so could generate significant revenue and profit growth.  Pfizer (NYSE: PFE) has been one of those companies, with danuglipron being a treatment it was hopeful could eventually come to market as a once-daily pill.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8948",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?",
                "url": "https://finance.yahoo.com/news/whats-next-pfizer-company-pulls-104000218.html"
            },
            {
                "headline": "Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it\u2019s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6705",
                "source": "StockStory",
                "ticker": "PFE",
                "title": "3 of Wall Street\u2019s Favorite Stocks Walking a Fine Line",
                "url": "https://finance.yahoo.com/news/3-wall-street-favorite-stocks-130400724.html"
            },
            {
                "headline": "PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3818",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?",
                "url": "https://finance.yahoo.com/news/pfizer-stock-q1-earnings-release-105800319.html"
            },
            {
                "headline": "Passive income is essential in retirement, but building a dependable stream isn't easy.  Fortunately, top-tier dividend stocks can do the heavy lifting.  In today's volatile market, where uncertainty is the only constant, dividend investing has regained its shine.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7012",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "2 High-Yield Dividend Stocks to Buy for Passive Income",
                "url": "https://finance.yahoo.com/news/2-high-yield-dividend-stocks-123000741.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer\u2019s Thoughts on These 5 Stocks. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discussed. On Thursday\u2019s episode of Mad Money, Jim Cramer addressed the growing friction between Federal Reserve Chairman Jerome Powell and [\u2026]",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3612",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Jim Cramer Warns on Pfizer (PFE): \u201cThat 7.7% Yield Is Not a Sign of Strength \u2013 It\u2019s a Sign of Weakness\u201d",
                "url": "https://finance.yahoo.com/news/jim-cramer-warns-pfizer-pfe-174450309.html"
            },
            {
                "headline": "Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill",
                "url": "https://finance.yahoo.com/m/e688a2ac-055a-3925-abe7-cd3cb5566982/novo-nordisk-pops-after.html"
            }
        ],
        "avgScore": 0.1263857142857143,
        "pctChange": 0.0029433141763627107
    },
    "4 22 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of the 10 Safe Dividend Stocks with Yields Above 5%. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other safe dividend stocks. Dividend-paying stocks have long held a special place among investors, often delivering stronger returns than the broader market over time. [\u2026]",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8779",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Pfizer Inc. (PFE): One of the Safe Dividend Stocks with Yields Above 5%",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-one-safe-141911199.html"
            },
            {
                "headline": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6486",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know",
                "url": "https://finance.yahoo.com/news/investors-heavily-search-pfizer-inc-130014658.html"
            },
            {
                "headline": "Investing.com -- Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and blood sugar control comparable to injectable treatments like Ozempic.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6249",
                "source": "Investing.com",
                "ticker": "PFE",
                "title": "Novo shares down on Eli Lilly\u2019s positive obesity pill data",
                "url": "https://finance.yahoo.com/news/novo-shares-down-eli-lilly-083401896.html"
            },
            {
                "headline": "We recently published a list of 15 Recent Activist Investor Campaigns. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other recent activist investor campaigns. Economic uncertainty and market volatility are some of the factors fueling activist investor campaigns in 2025. In the first quarter alone, there [\u2026]",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Pfizer Inc. (PFE): Among Recent Activist Investor Campaigns",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-among-recent-133604076.html"
            },
            {
                "headline": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for",
                "url": "https://finance.yahoo.com/news/analysts-estimate-pfizer-pfe-report-140058650.html"
            },
            {
                "headline": "Investing.com -- Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and blood sugar control comparable to injectable treatments like Ozempic.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6249",
                "source": "Investing.com",
                "ticker": "PFE",
                "title": "Novo shares down on Eli Lilly\u2019s positive obesity pill data",
                "url": "https://finance.yahoo.com/news/novo-shares-down-eli-lilly-083401896.html"
            }
        ],
        "avgScore": 0.3702,
        "pctChange": -0.006213994351098935
    },
    "4 21 2025": {
        "importantArticles": [
            {
                "headline": "Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q1 2025 earnings on April 29. Wall Street analysts expect the company to post EPS of $0.70, down from $0.82 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $14.27 billion, down from $14.88 billion a year earlier. The 52-week range of Pfizer stock price was $20.92 to $31.54. Pfizer's d",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Benzinga",
                "ticker": "PFE",
                "title": "How To Put $100 In Your Retirement Fund Each Month With Pfizer Stock",
                "url": "https://finance.yahoo.com/news/put-100-retirement-fund-month-020059807.html"
            },
            {
                "headline": "SpringWorks Therapeutics and the Children\u2019s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "Pharma Voice",
                "ticker": "PFE",
                "title": "How a scrapped Pfizer drug became a winner for SpringWorks",
                "url": "https://finance.yahoo.com/news/scrapped-pfizer-drug-became-winner-080000858.html"
            },
            {
                "headline": "SpringWorks Therapeutics and the Children\u2019s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "Pharma Voice",
                "ticker": "PFE",
                "title": "How a scrapped Pfizer drug became a winner for SpringWorks",
                "url": "https://finance.yahoo.com/news/scrapped-pfizer-drug-became-winner-080000858.html"
            },
            {
                "headline": "Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q1 2025 earnings on April 29. Wall Street analysts expect the company to post EPS of $0.70, down from $0.82 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $14.27 billion, down from $14.88 billion a year earlier. The 52-week range of Pfizer stock price was $20.92 to $31.54. Pfizer's d",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Benzinga",
                "ticker": "PFE",
                "title": "How To Put $100 In Your Retirement Fund Each Month With Pfizer Stock",
                "url": "https://finance.yahoo.com/news/put-100-retirement-fund-month-020059807.html"
            }
        ],
        "avgScore": -0.0129,
        "pctChange": 0.0222322935918281
    },
    "4 17 2025": {
        "importantArticles": [
            {
                "headline": "Tariff uncertainty has created an ideal opportunity for long-term investors to pounce.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7003",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Trump Tariff Plunge: 3 Phenomenal Stocks to Buy at Bargain Prices Right Now",
                "url": "https://finance.yahoo.com/news/trump-tariff-plunge-3-phenomenal-075100309.html"
            },
            {
                "headline": "NEW YORK, April 16, 2025--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention\u2019s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO\u00ae (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug A",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "ACIP Votes to Expand Recommendation for Pfizer\u2019s RSV Vaccine ABRYSVO\u00ae to Include Adults Aged 50 to 59 at Increased Risk of Disease",
                "url": "https://finance.yahoo.com/news/acip-votes-expand-recommendation-pfizer-201500828.html"
            },
            {
                "headline": "JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback",
                "url": "https://finance.yahoo.com/news/pharma-stock-roundup-j-js-131500764.html"
            },
            {
                "headline": "The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59",
                "url": "https://finance.yahoo.com/news/gsk-pfes-rsv-vaccines-recommended-132000369.html"
            },
            {
                "headline": "JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback",
                "url": "https://finance.yahoo.com/news/pharma-stock-roundup-j-js-131500764.html"
            },
            {
                "headline": "NEW YORK, April 16, 2025--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention\u2019s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO\u00ae (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug A",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "ACIP Votes to Expand Recommendation for Pfizer\u2019s RSV Vaccine ABRYSVO\u00ae to Include Adults Aged 50 to 59 at Increased Risk of Disease",
                "url": "https://finance.yahoo.com/news/acip-votes-expand-recommendation-pfizer-201500828.html"
            }
        ],
        "avgScore": 0.10025,
        "pctChange": -0.004516643038745885
    },
    "4 16 2025": {
        "importantArticles": [
            {
                "headline": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts \u201climited reaction\u201d in Pfizer\u2019s shares following the news, JPMorgan tells investors that the decision is \u201cmostly a positive\u201d for Structure and Viking, both developing drugs in the",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
                "url": "https://finance.yahoo.com/news/smaller-obesity-drugmakers-jump-pfizer-143525028.html"
            },
            {
                "headline": "On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (NYSE: PFE).  On Tuesday, Pfizer's stock closed the day 1.5% higher, providing a pleasant contrast to the S&P 500 index's 0.2% dip.  Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug danuglipron.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4939",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Why Pfizer Stock Topped the Market on Tuesday",
                "url": "https://finance.yahoo.com/news/why-pfizer-stock-topped-market-225308409.html"
            },
            {
                "headline": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
                "url": "https://finance.yahoo.com/news/pfizer-halts-obesity-pill-development-165700605.html"
            },
            {
                "headline": "BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of liver injury seen in the phase 1 study. The firm points out that it has argued that this program has received almost too much attention \u2013 not because obesity isn\u2019t important, but because this was only phase 1 data. Without danuglipron, Pfizer\u2019s obesity pipeline now consists of a GIP receptor antagonist in phase 2 and a phase 1 oral GLP-1 in T2D with Nxera Pharma.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7269",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged",
                "url": "https://finance.yahoo.com/news/bofa-keeps-neutral-pfizer-danuglipron-150532621.html"
            },
            {
                "headline": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
                "url": "https://finance.yahoo.com/news/pfizer-halts-obesity-pill-development-165700605.html"
            },
            {
                "headline": "On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (NYSE: PFE).  On Tuesday, Pfizer's stock closed the day 1.5% higher, providing a pleasant contrast to the S&P 500 index's 0.2% dip.  Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug danuglipron.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4939",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Why Pfizer Stock Topped the Market on Tuesday",
                "url": "https://finance.yahoo.com/news/why-pfizer-stock-topped-market-225308409.html"
            }
        ],
        "avgScore": -0.031950000000000006,
        "pctChange": 0.004537135660944737
    },
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of the 11 Best Dividend Paying Stocks According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best dividend-paying stocks. Dividend-paying stocks have consistently attracted investor interest due to their long-term value. CNBC highlights this by examining the [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9485",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer Inc. (PFE) Among the Best Dividend Paying Stocks According to Hedge Funds?",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-among-best-142115898.html"
            },
            {
                "headline": "Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.4% and the",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7506",
                "source": "MT Newswires",
                "ticker": "PFE",
                "title": "Sector Update: Health Care Stocks Rise Monday Afternoon",
                "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-180801475.html"
            },
            {
                "headline": "Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7269",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback",
                "url": "https://finance.yahoo.com/news/nvo-lly-gpcr-vktx-stocks-140000975.html"
            },
            {
                "headline": "Pfizer tanks after liver injury kills obesity pill hopes--Lilly, Novo, and Viking surge as investors jump ship",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.743",
                "source": "GuruFocus.com",
                "ticker": "PFE",
                "title": "Pfizer's $130B Weight-Loss Dream Just Collapsed",
                "url": "https://finance.yahoo.com/news/pfizers-130b-weight-loss-dream-151831937.html"
            },
            {
                "headline": "Pfizer Inc. will stop developing an obesity pill after the treatment was linked to a potentially drug-related liver injury in a clinical trial patient. The company won't advance the once-daily medicine into the final stage of testing and will instead invest in earlier-stage treatments for obesity. Damian Garde reports on Bloomberg Television.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.6124",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Pfizer Abandons Obesity Pill After Trial Liver Injury",
                "url": "https://finance.yahoo.com/video/pfizer-abandons-obesity-pill-trial-140656016.html"
            },
            {
                "headline": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergHow Did This Suburb Figure Out Mass Transit?The Secret Formula for Faster TrainsEven Oslo Has an Air Quality ProblemNYC Tourist Helicopter Crashes in Hudson River, Killing SixLisbon Mayor Wants Companies to Help Fix City\u2019s Housing ShortagePresident Donald Trump\u2019s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5994",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Trump Initiates Chips and Drug Probes\u00a0Ahead of More Tariffs",
                "url": "https://finance.yahoo.com/news/trump-announces-chips-drug-probes-204108780.html"
            }
        ],
        "avgScore": -0.02262173913043475,
        "pctChange": -0.017825294519186234
    },
    "4 14 2025": {
        "importantArticles": [
            {
                "headline": "Stocks are looking to extend their strongest weekly rally since late 2023.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "TheStreet",
                "ticker": "PFE",
                "title": "Stock Market Today: Stocks end higher, tech stalls amid tariff confusion",
                "url": "https://finance.yahoo.com/news/stock-market-today-stocks-higher-100900834.html"
            },
            {
                "headline": "Pfizer ends its most advanced clinical trial of an obesity pill to compete in the hot GLP-1 space.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3167",
                "source": "Yahoo Finance",
                "ticker": "PFE",
                "title": "Pfizer discontinues GLP-1 pill trial, stock trades flat",
                "url": "https://finance.yahoo.com/news/pfizer-discontinues-glp-1-pill-trial-stock-trades-flat-135330797.html"
            },
            {
                "headline": "Investing.com -- Shares of Pfizer Inc (NYSE:PFE) dipped 1.5% as the pharmaceutical giant announced the discontinuation of its drug candidate danuglipron, which was under investigation for chronic weight management.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.296",
                "source": "Investing.com",
                "ticker": "PFE",
                "title": "Pfizer pulls plug on weight-loss pill, citing trial concerns",
                "url": "https://finance.yahoo.com/news/pfizer-pulls-plug-weight-loss-112112412.html"
            },
            {
                "headline": "Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it break into the highly lucrative market for obesity drugs.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2023",
                "source": "BioPharma Dive",
                "ticker": "PFE",
                "title": "Safety worries spur Pfizer to drop another obesity pill",
                "url": "https://finance.yahoo.com/news/safety-worries-spur-pfizer-drop-120500830.html"
            },
            {
                "headline": "Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.  The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment.  The once-daily version of the pill was in early-stage testing, with researchers trying to figure out the best dose for patients, a spokeswoman said.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1779",
                "source": "Associated Press Finance",
                "ticker": "PFE",
                "title": "Pfizer ends development of potential pill obesity treatment",
                "url": "https://finance.yahoo.com/news/pfizer-ends-development-potential-pill-124143941.html"
            },
            {
                "headline": "NEW YORK, April 14, 2025--Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron",
                "url": "https://finance.yahoo.com/news/pfizer-provides-oral-glp-1-104500492.html"
            }
        ],
        "avgScore": 0.11284285714285713,
        "pctChange": 0.014466531766881651
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "NEW YORK, April 10, 2025--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24",
                "url": "https://finance.yahoo.com/news/pfizer-invites-shareholders-attend-virtual-150000793.html"
            },
            {
                "headline": "A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries. This reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6249",
                "source": "StockStory",
                "ticker": "PFE",
                "title": "Select Medical, Phreesia, Eli Lilly, Pfizer, and Brink's Shares Are Falling, What You Need To Know",
                "url": "https://finance.yahoo.com/news/select-medical-phreesia-eli-lilly-171104703.html"
            },
            {
                "headline": "Though the stock market is still historically pricey, a few phenomenal bargains have cropped up.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility",
                "url": "https://finance.yahoo.com/news/6-stocks-clear-price-dislocations-070600692.html"
            },
            {
                "headline": "Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "S&P, Dow Jones Pharma Names Rattled \u2014 Again \u2014 On Trump's Tariffs Whiplash",
                "url": "https://finance.yahoo.com/m/5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1/s-p-dow-jones-pharma-names.html"
            },
            {
                "headline": "The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.25",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Vaxcyte Stock Plummets 56% in a Month: Here's the Reason",
                "url": "https://finance.yahoo.com/news/vaxcyte-stock-plummets-56-month-170700030.html"
            },
            {
                "headline": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock",
                "url": "https://finance.yahoo.com/news/know-beyond-why-pfizer-inc-130014887.html"
            }
        ],
        "avgScore": 0.07592857142857144,
        "pctChange": 0.009584709871465072
    },
    "4 10 2025": {
        "importantArticles": [
            {
                "headline": "PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors due to its sky-high dividend yield.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8225",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?",
                "url": "https://finance.yahoo.com/news/pfizer-stock-falls-52-week-134400344.html"
            },
            {
                "headline": "Catalysts host Madison Mills and Trader Talk podcast host Kenny Polcari take a look at some of the day's top trending stocks. Apple (AAPL) is in focus after Microsoft (MSFT) replaced Apple as the most valuable company. Alibaba (BABA) reverses earlier gains after US tariffs went into effect. Drugmaker stocks, including Pfizer (PFE), Merck (MRK), and Eli Lilly (LLY), are falling after President Trump announced that pharmaceutical tariffs may be on the way. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7178",
                "source": "Yahoo Finance Video",
                "ticker": "PFE",
                "title": "Apple, Alibaba, drugmaker stocks: Trending Tickers",
                "url": "https://finance.yahoo.com/video/apple-alibaba-drugmaker-stocks-trending-144322260.html"
            },
            {
                "headline": "Three companies recently announced progression in their clinical research for next-generation Covid-19 vaccines: INOVIO, Ocugen, and Pfizer.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Clinical Trials Arena",
                "ticker": "PFE",
                "title": "Next-generation Covid-19 vaccines currently being tested",
                "url": "https://finance.yahoo.com/news/next-generation-covid-19-vaccines-103050825.html"
            },
            {
                "headline": "Drugmaker stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE), are under pressure on Wednesday after President Trump announced that he may impose tariffs on pharmaceutical imports. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Yahoo Finance Video",
                "ticker": "PFE",
                "title": "Trump says pharmaceutical tariffs may be coming: What to know",
                "url": "https://finance.yahoo.com/video/trump-says-pharmaceutical-tariffs-may-141157823.html"
            },
            {
                "headline": "Catalysts host Madison Mills goes over some of the top stories of the day on this segment of Market Minute. Delta Air Lines (DAL) cut its full-year guidance as uncertainty around tariffs weighs on bookings. Walmart (WMT) walks back its first quarter profit guidance, citing tariff risks. Pharmaceutical stocks, including Pfizer (PFE), Novo Nordisk (NVO), and Eli Lilly (LLY), are under pressure after President Trump announced that there may be pharmaceutical tariffs underway. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4767",
                "source": "Yahoo Finance Video",
                "ticker": "PFE",
                "title": "Delta, Walmart, pharmaceutical stocks: Market Minute",
                "url": "https://finance.yahoo.com/video/delta-walmart-pharmaceutical-stocks-market-151538726.html"
            },
            {
                "headline": "General Motors, JD.com, Pfizer, StoneCo and Enersys have been highlighted in this Screen of The Week article.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Zacks.com featured highlights General Motors, JD.com, Pfizer, StoneCo and Enersys",
                "url": "https://finance.yahoo.com/news/zacks-com-featured-highlights-general-090000004.html"
            }
        ],
        "avgScore": 0.08948333333333336,
        "pctChange": 0.01482166246237205
    },
    "4 9 2025": {
        "importantArticles": [
            {
                "headline": "The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, JD, PFE, STNE and ENS are some such stocks.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7506",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "5 Low Price-to-Book Stocks to Add to Your Portfolio in April",
                "url": "https://finance.yahoo.com/news/5-low-price-book-stocks-125800063.html"
            },
            {
                "headline": "If you're a dividend investor, now can be an ideal time to go bargain-hunting.  The stock market is in the midst of a broad sell-off, with investors dumping all types of stocks, both bad ones and good ones.  Three dividend stocks that are near their 52-week lows and which may make for solid income-generating investments are Pfizer (NYSE: PFE), Lockheed Martin (NYSE: LMT), and Rogers Communications (NYSE: RCI).",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.0772",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now",
                "url": "https://finance.yahoo.com/news/3-high-yielding-dividend-stocks-093200831.html"
            },
            {
                "headline": "Pharma names whipsawed Wednesday after Trump said he would enact \"major\" tariffs on drug imports and then backed off his tariffs \u2014 for now.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan",
                "url": "https://finance.yahoo.com/m/be7d1b24-7c1e-38ff-91b2-281ea7807568/dow-jones-s-p-500-pharma.html"
            },
            {
                "headline": "Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.  AbbVie, Eli Lilly, Johnson & Johnson, Merck and Pfizer were all down at least 2.5% in Wednesday midday trading.  Denmark's Novo Nordisk, Switzerland's Novartis and the U.K.'s AstraZeneca and GSK fell 2% or more in the U.S.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7506",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
                "url": "https://finance.yahoo.com/m/f171bfb7-94e2-3b98-bde2-9d5add357a5c/novo-nordisk-abbvie-stocks.html"
            },
            {
                "headline": "David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5778",
                "source": "Simply Wall St.",
                "ticker": "PFE",
                "title": "Is Pfizer (NYSE:PFE) A Risky Investment?",
                "url": "https://finance.yahoo.com/news/pfizer-nyse-pfe-risky-investment-130015999.html"
            },
            {
                "headline": "Trump tariff news: President Trump's latest tariffs took effect Wednesday while China stepped up retaliation. Treasury yields are worrisome. Walmart and Delta Air pulled some guidance, citing tariff uncertainty.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5106",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "Trump Tariff News: New Tariffs Begin, China Retaliates; Treasury Yields Spike While Delta, Walmart Pull Guidance",
                "url": "https://finance.yahoo.com/m/a3b4073e-cf6b-3c9f-8915-5acaa3968de0/trump-tariff-news-new.html"
            }
        ],
        "avgScore": -0.18667777777777778,
        "pctChange": -0.04001776912803975
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9081",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Is Pfizer (PFE) Stock Undervalued Right Now?",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-stock-undervalued-now-134010049.html"
            },
            {
                "headline": "Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading Eli Lilly (NYSE:LLY) to a Buy on strong growth prospects in obesity treatments.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7717",
                "source": "Investing.com",
                "ticker": "PFE",
                "title": "Goldman turns cautious on major pharma names, sees select upside at Eli Lilly",
                "url": "https://finance.yahoo.com/news/goldman-turns-cautious-major-pharma-130817424.html"
            },
            {
                "headline": "The narrative around Pfizer couldn't be much worse. That makes the stock very interesting at these prices.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6754",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Down 62%, Should You Buy the Dip on Pfizer?",
                "url": "https://finance.yahoo.com/news/down-62-buy-dip-pfizer-084000869.html"
            },
            {
                "headline": "(Bloomberg) -- Drug manufacturers are rushing to reshape their supply chains amid President Donald Trump\u2019s escalating tariff threats, leading to a potential windfall for contractors that make medications in the US.Most Read from BloombergHousing Agency Aims to Relocate Its DC HeadquartersThis Skinny Mexico City Tower Is Just 14 Feet Wide on One SideThe Irish Hot Press Is the Low-Tech Laundry Trick the World NeedsBoston Mayor Wu Embraces Trump Resistance as Campaign Heats UpTrump Order on CDFI Fu",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8271",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Trump\u2019s Tariff Threat Sparks Race to Find US Drug Manufacturers",
                "url": "https://finance.yahoo.com/news/trump-tariff-threat-sparks-race-191812489.html"
            },
            {
                "headline": "European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis",
                "url": "https://finance.yahoo.com/news/abbvies-rinvoq-gets-eu-nod-131500800.html"
            },
            {
                "headline": "The narrative around Pfizer couldn't be much worse. That makes the stock very interesting at these prices.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6754",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Down 62%, Should You Buy the Dip on Pfizer?",
                "url": "https://finance.yahoo.com/news/down-62-buy-dip-pfizer-084000869.html"
            }
        ],
        "avgScore": 0.386,
        "pctChange": 0.029761887087407044
    },
    "4 7 2025": {
        "importantArticles": [
            {
                "headline": "In mid-March here, I (Tom Yeung) wrote about three stocks to sell on an escalating trade war. President Donald Trump was ratcheting his tariff rhetoric, so we highlighted three import-reliant firms to sell: Deckers Outdoor Corp. (DECK) Abercrombie & Fitch Co. (ANF) Toll Brothers Inc. (TOL) That\u2019s because \u201ceggs in the same basket\u201d strategies cut both ways. During normal times, a firm like UGG boots maker Deckers saves millions by sourcing its sheepskin through just two Chinese tanneries. But much",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3071",
                "source": "InvestorPlace",
                "ticker": "PFE",
                "title": "Sell or Buy? What Navellier Is Doing After \u2018Liberation Day.\u2019",
                "url": "https://finance.yahoo.com/news/sell-buy-navellier-doing-liberation-160000304.html"
            },
            {
                "headline": "In mid-March here, I (Tom Yeung) wrote about three stocks to sell on an escalating trade war. President Donald Trump was ratcheting his tariff rhetoric, so we highlighted three import-reliant firms to sell: Deckers Outdoor Corp. (DECK) Abercrombie & Fitch Co. (ANF) Toll Brothers Inc. (TOL) That\u2019s because \u201ceggs in the same basket\u201d strategies cut both ways. During normal times, a firm like UGG boots maker Deckers saves millions by sourcing its sheepskin through just two Chinese tanneries. But much",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3071",
                "source": "InvestorPlace",
                "ticker": "PFE",
                "title": "Sell or Buy? What Navellier Is Doing After \u2018Liberation Day.\u2019",
                "url": "https://finance.yahoo.com/news/sell-buy-navellier-doing-liberation-160000304.html"
            }
        ],
        "avgScore": -0.3071,
        "pctChange": -0.03490936975147238
    },
    "4 4 2025": {
        "importantArticles": [
            {
                "headline": "FDA approves SNY's hemophilia therapy, fitusiran, and NVS' rare kidney disease drug, Vanrafia.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure",
                "url": "https://finance.yahoo.com/news/pharma-stock-roundup-fda-nod-134600557.html"
            },
            {
                "headline": "Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-130400151.html"
            },
            {
                "headline": "(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court.  GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled.  GSK, Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "Reuters",
                "ticker": "PFE",
                "title": "GSK resolves patent lawsuit against Pfizer over RSV vaccines",
                "url": "https://finance.yahoo.com/news/gsk-resolves-patent-lawsuit-against-220317477.html"
            },
            {
                "headline": "Is Pfizer stock a sell now after HHS fired thousands of employees, putting new drug approvals in limbo?",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5574",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "Is Pfizer Stock A Sell As HHS Firings, Tariffs Cast A Pall On Pharma?",
                "url": "https://finance.yahoo.com/m/9a6f7dfd-febf-37fb-912a-e0504d778fbc/is-pfizer-stock-a-sell-as-hhs.html"
            },
            {
                "headline": "(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court.  GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled.  GSK, Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "Reuters",
                "ticker": "PFE",
                "title": "GSK resolves patent lawsuit against Pfizer over RSV vaccines",
                "url": "https://finance.yahoo.com/news/gsk-resolves-patent-lawsuit-against-220317477.html"
            },
            {
                "headline": "Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-130400151.html"
            }
        ],
        "avgScore": -0.07330000000000002,
        "pctChange": -0.01480192262740811
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).  If Pfizer and Moderna can bounce back, purchasing their shares now might be a great move -- but which is the more attractive option?  Pfizer has made important moves in the past few years that could pay off down the line.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9577",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna",
                "url": "https://finance.yahoo.com/news/better-beaten-down-stock-buy-123000684.html"
            },
            {
                "headline": "Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road.  As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.  Stocks normally trade at discounts when there are concerns or question marks about the company's future performance.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9325",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "2 Absurdly Cheap Stocks to Buy and Hold for Years",
                "url": "https://finance.yahoo.com/news/2-absurdly-cheap-stocks-buy-084000763.html"
            },
            {
                "headline": "Both JNJ & PFE expect their sales and profits to improve in 2025.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7003",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "JNJ vs. PFE: Which Drug Giant is a Better Buy Now?",
                "url": "https://finance.yahoo.com/news/jnj-vs-pfe-drug-giant-135900061.html"
            },
            {
                "headline": "Pfizer\u2019s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The pharmaceutical giant, best known for its COVID-19 products (Paxlovid and Comirnaty), Eliquis, and Prevnar, a pneumococcal vaccine, has been dealing with difficult year-over-year comps due to a withering COVID-19 portfolio. Moreover, many of Pfizer\u2019s products, like Eliquis (2027 to 2029) and Ibrance (2027), face \u201cpatent cliffs.\u201d That means their time for market exclusivity is",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump",
                "url": "https://finance.yahoo.com/news/potential-stock-woe-ahead-pfizer-164324539.html"
            },
            {
                "headline": "In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-increases-yet-falls-214515191.html"
            },
            {
                "headline": "Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year.  If you're a growth investor, you probably won't be interested in buying Pfizer stock.  Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0108",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Is Pfizer Stock a Buy?",
                "url": "https://finance.yahoo.com/news/pfizer-stock-buy-094700982.html"
            }
        ],
        "avgScore": 0.42175000000000007,
        "pctChange": -0.054343415085218984
    },
    "4 2 2025": {
        "importantArticles": [
            {
                "headline": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-beat-estimates-again-161013995.html"
            },
            {
                "headline": "(Reuters) -Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its upcoming annual meeting, citing concerns about certain changes made to long-term awards to its CEO and others.  The modifications, including repeated changes to Pfizer's cash flow targets, and a lack of clarity about certain pipeline goals are concerning and undermine a \"pay-for-performance philosophy\", ISS said.  Annual incentives for executives are tied to achieving three financial goals, and payouts can be 30 percentage points higher or lower based on pipeline and ESG-related goals achieved, ISS said.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Reuters",
                "ticker": "PFE",
                "title": "Proxy adviser ISS recommends against Pfizer executive pay proposal",
                "url": "https://finance.yahoo.com/news/proxy-adviser-iss-recommends-pfizer-131020223.html"
            },
            {
                "headline": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4215",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
                "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-130009469.html"
            },
            {
                "headline": "Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters",
                "url": "https://finance.yahoo.com/news/pfe-mrk-lly-other-drug-134300035.html"
            },
            {
                "headline": "The latest investor updates on stocks that are trending on Wednesday.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Yahoo Finance UK",
                "ticker": "PFE",
                "title": "Trending tickers: Tesla, Johnson & Johnson, CoreWeave, Newsmax and Raspberry Pi",
                "url": "https://finance.yahoo.com/news/tesla-johnson-johnson-coreweave-newsmax-raspberry-pi-trending-tickers-094114477.html"
            },
            {
                "headline": "Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include younger adults, and announced a collaboration with Flagship Pioneering for autoimmune therapeutics. Despite this positive news, Pfizer's share price declined by 3% last week, aligning somewhat with the broader market's 3.4% drop amid heightened investor anxiety over impending U.S. tariffs. While rotation into big tech buoyed by Tesla's gains contrasted the broader downturn,...",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0245",
                "source": "Simply Wall St.",
                "ticker": "PFE",
                "title": "Pfizer (NYSE:PFE) Expands RSV Vaccine Use In Europe Amid 3% Share Price Dip",
                "url": "https://finance.yahoo.com/news/pfizer-nyse-pfe-expands-rsv-173433656.html"
            }
        ],
        "avgScore": 0.269525,
        "pctChange": -0.0165991835930339
    },
    "4 1 2025": {
        "importantArticles": [
            {
                "headline": "March winds bring April showers.  Seriously, there are several great ultra-high-yield dividend stocks to buy in April.  Ares Capital (NASDAQ: ARCC) offers such a high dividend yield, at 8.68%, that you might wonder if it's sustainable.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "3 Ultra-High-Yield Dividend Stocks to Buy in April",
                "url": "https://finance.yahoo.com/news/3-ultra-high-yield-dividend-095000907.html"
            },
            {
                "headline": "Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1531",
                "source": "Pharmaceutical Technology",
                "ticker": "PFE",
                "title": "Pfizer\u2019s RSV vaccine wins expanded approval in EU, gaining edge over GSK",
                "url": "https://finance.yahoo.com/news/pfizer-rsv-vaccine-wins-expanded-113100409.html"
            },
            {
                "headline": "We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade in [\u2026]",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer Inc. (PFE) the Most Undervalued Healthcare Stock to Buy According to Analysts?",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-most-undervalued-140133307.html"
            },
            {
                "headline": "The health agency\u2019s top immunization official announced the move Monday in protest, citing Secretary Kennedy\u2019s \u2018misinformation and lies.\u2019",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "FastCompany",
                "ticker": "PFE",
                "title": "Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr.\u00a0anti-vax views",
                "url": "https://finance.yahoo.com/news/vaccine-stocks-tumble-moderna-novavax-183000390.html"
            },
            {
                "headline": "NEW YORK, April 01, 2025--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO\u00ae, the company\u2019s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now of",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "European Commission Approves Pfizer\u2019s RSV Vaccine ABRYSVO\u00ae to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease",
                "url": "https://finance.yahoo.com/news/european-commission-approves-pfizer-rsv-070000511.html"
            },
            {
                "headline": "Dr. Mikael Dolsten, Pfizer\u2019s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Pharma Voice",
                "ticker": "PFE",
                "title": "Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the \u2018big questions\u2019",
                "url": "https://finance.yahoo.com/news/former-pfizer-cso-mikael-dolsten-080000530.html"
            }
        ],
        "avgScore": 0.10039999999999999,
        "pctChange": 0.0065199609389937595
    },
    "3 31 2025": {
        "importantArticles": [
            {
                "headline": "Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration\u2019s top vaccine official has been pushed out. Shares in some larger drugmakers, such as GSK, also retreated.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out",
                "url": "https://finance.yahoo.com/m/2f2d481b-21ce-368a-a644-24dbc4039d4b/moderna-novavax-stocks-fall.html"
            },
            {
                "headline": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?",
                "url": "https://finance.yahoo.com/news/trending-stock-pfizer-inc-pfe-130013223.html"
            },
            {
                "headline": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?",
                "url": "https://finance.yahoo.com/news/trending-stock-pfizer-inc-pfe-130013223.html"
            },
            {
                "headline": "Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration\u2019s top vaccine official has been pushed out. Shares in some larger drugmakers, such as GSK, also retreated.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out",
                "url": "https://finance.yahoo.com/m/2f2d481b-21ce-368a-a644-24dbc4039d4b/moderna-novavax-stocks-fall.html"
            }
        ],
        "avgScore": 0.2374,
        "pctChange": -0.03157060900723182
    },
    "3 28 2025": {
        "importantArticles": [
            {
                "headline": "Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index up 0.3% and",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7506",
                "source": "MT Newswires",
                "ticker": "PFE",
                "title": "Sector Update: Health Care Stocks Advance Late Afternoon",
                "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-195816814.html"
            },
            {
                "headline": "The approval is based on open-label Phase III innovaTV 301 clinical trial data.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Pharmaceutical Technology",
                "ticker": "PFE",
                "title": "Genmab\u2019s Tivdak approved in Japan for advanced cervical cancer",
                "url": "https://finance.yahoo.com/news/genmab-tivdak-approved-japan-advanced-093443945.html"
            },
            {
                "headline": "The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive",
                "url": "https://finance.yahoo.com/news/merck-gets-ec-nod-21-153400793.html"
            },
            {
                "headline": "(Update with Pfizer's response to a request for comment.) Pfizer (PFE) sold $20 billion of drugs",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "MT Newswires",
                "ticker": "PFE",
                "title": "Update: Sen. Ron Wyden Accuses Pfizer of Tax Dodging After Concluding Investigation",
                "url": "https://finance.yahoo.com/news/sen-ron-wyden-accuses-pfizer-185224734.html"
            },
            {
                "headline": "The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive",
                "url": "https://finance.yahoo.com/news/merck-gets-ec-nod-21-153400793.html"
            },
            {
                "headline": "The approval is based on open-label Phase III innovaTV 301 clinical trial data.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Pharmaceutical Technology",
                "ticker": "PFE",
                "title": "Genmab\u2019s Tivdak approved in Japan for advanced cervical cancer",
                "url": "https://finance.yahoo.com/news/genmab-tivdak-approved-japan-advanced-093443945.html"
            }
        ],
        "avgScore": 0.4073,
        "pctChange": 0.005156726411596922
    },
    "3 27 2025": {
        "importantArticles": [
            {
                "headline": "Donald Trump\u2019s justice department is investigating claims that Pfizer delayed positive news about its Covid-19 vaccine until after the 2020 election.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7269",
                "source": "The Telegraph",
                "ticker": "PFE",
                "title": "GSK accuses Pfizer of delaying Covid vaccine result until after US election",
                "url": "https://finance.yahoo.com/news/gsk-accuses-pfizer-delaying-covid-140642612.html"
            },
            {
                "headline": "Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion that the pharmaceutical giant delayed announcing a successful Covid-19 vaccine until after the 2020 election.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Pfizer Stock Slips After Report on Vaccine Timing Probe",
                "url": "https://finance.yahoo.com/m/7edf436c-1971-3b95-973d-6615a7f6abe3/pfizer-stock-slips-after.html"
            },
            {
                "headline": "With its stock down 5.4% over the past month, it is easy to disregard Pfizer (NYSE:PFE). We, however decided to study...",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Simply Wall St.",
                "ticker": "PFE",
                "title": "Is Pfizer Inc.'s (NYSE:PFE) Recent Price Movement Underpinned By Its Weak Fundamentals?",
                "url": "https://finance.yahoo.com/news/pfizer-inc-nyse-pfe-recent-140013227.html"
            },
            {
                "headline": "Healthcare stocks have been out of vogue with investors since late 2022.  Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted.  Pharmaceutical titan Pfizer (NYSE: PFE) is a case in point.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3291",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Why Pfizer Is My Largest Healthcare Position",
                "url": "https://finance.yahoo.com/news/why-pfizer-largest-healthcare-position-104500478.html"
            },
            {
                "headline": "In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Here's Why Pfizer (PFE) Fell More Than Broader Market",
                "url": "https://finance.yahoo.com/news/heres-why-pfizer-pfe-fell-214515204.html"
            },
            {
                "headline": "(Updates with Pfizer's response to a request for comment from MT Newswires in the second and third p",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "MT Newswires",
                "ticker": "PFE",
                "title": "Update: Market Chatter: US Prosecutors Investigate Tip on Pfizer Vaccine",
                "url": "https://finance.yahoo.com/news/market-chatter-us-prosecutors-investigate-123554313.html"
            }
        ],
        "avgScore": 0.152425,
        "pctChange": 0.007996755448241034
    },
    "3 26 2025": {
        "importantArticles": [
            {
                "headline": "Undervalued, Strong Pipeline, Positioned for Growth Potential.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7096",
                "source": "GuruFocus.com",
                "ticker": "PFE",
                "title": "Pfizer: Undervalued Defensive Play",
                "url": "https://finance.yahoo.com/news/pfizer-undervalued-defensive-play-211251970.html"
            },
            {
                "headline": "ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.1",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3182",
                "source": "CNW Group",
                "ticker": "PFE",
                "title": "ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program",
                "url": "https://finance.yahoo.com/news/viiv-healthcare-announces-reimbursement-apretude-130100708.html"
            },
            {
                "headline": "ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.1",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3182",
                "source": "CNW Group",
                "ticker": "PFE",
                "title": "ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program",
                "url": "https://finance.yahoo.com/news/viiv-healthcare-announces-reimbursement-apretude-130100708.html"
            },
            {
                "headline": "Undervalued, Strong Pipeline, Positioned for Growth Potential.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7096",
                "source": "GuruFocus.com",
                "ticker": "PFE",
                "title": "Pfizer: Undervalued Defensive Play",
                "url": "https://finance.yahoo.com/news/pfizer-undervalued-defensive-play-211251970.html"
            }
        ],
        "avgScore": 0.5139,
        "pctChange": -0.007933314670923713
    },
    "3 25 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 14 Best Affordable Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best affordable stocks to invest in. The broader market has taken a significant hit, dropping 10% from its peak and wiping [\u2026]",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8807",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer (PFE) The Best Affordable Stock To Buy According To Hedge Funds?",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-best-affordable-stock-201957885.html"
            },
            {
                "headline": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5423",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "5 Large Drug Stocks to Watch as Industry Recovers",
                "url": "https://finance.yahoo.com/news/5-large-drug-stocks-watch-104700001.html"
            },
            {
                "headline": "Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day",
                "url": "https://finance.yahoo.com/news/broadcom-crown-castle-box-highlighted-062000144.html"
            },
            {
                "headline": "Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day",
                "url": "https://finance.yahoo.com/news/broadcom-crown-castle-box-highlighted-062000144.html"
            },
            {
                "headline": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5423",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "5 Large Drug Stocks to Watch as Industry Recovers",
                "url": "https://finance.yahoo.com/news/5-large-drug-stocks-watch-104700001.html"
            },
            {
                "headline": "We recently published a list of 14 Best Affordable Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best affordable stocks to invest in. The broader market has taken a significant hit, dropping 10% from its peak and wiping [\u2026]",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8807",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer (PFE) The Best Affordable Stock To Buy According To Hedge Funds?",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-best-affordable-stock-201957885.html"
            }
        ],
        "avgScore": 0.47433333333333333,
        "pctChange": -0.013307247073992737
    },
    "coef": 0.0536420101637493,
    "avgCoef": -0.0034441938237061626,
    "similar": {
        "NEE": 0.3233766233766234,
        "PBR": 0.3116883116883117,
        "CMG": 0.3103896103896104,
        "ADT": 0.3025974025974026
    }
}